

S1 Table. Study group, characteristic of subgroups with TF<450pg/ml and >450pg/ml

Parameter	TF		p-value
	< 450 pg/ml	>450 pg/ml	
Route of infection HTX/IDU/MSM (%)	24.8 / 47.5 / 27.7	38.9 /27.8 / 33.3	0.1
Duration of HIV infection, (years)*	8 (3 -7 23)	11 (8 - 18)	0.059
AIDS, n (%)	30 (29.7%)	3 (16%)	0.26
HCV co-infection, n (%)	25 (24.75%)	1 (5.6%)	0.069
Past HBV infection, n (%)	56 (55.45%)	8 (44.45%)	0.39
Current CD4+ T cells (cells/ μ l) *	499 (384 - 648)	673 (477 - 794)	0.031
Nadir CD4+ T cells, (cells/ μ m)*	233 (93 - 349)	137 (46 - 274)	0.086
Current HIV RNA, (copies/ml)*	40 (40 - 50)	44.5 (40 - 49)	0.29
Undetectable HIV RNA, n (%)	22 (22.5%)	18 (100%)	0.026
Zenith HIV RNA (copies/ml)*	32150 (6581– 149720)	64300 (35825 - 226130)	0.07
ARV treatment, n (%)	88 (87.12%)	18 (100%)	0.11
Duration of ARV treatment, (years)*	4 (1.6 - 8)	9 (6 - 11)	0.002
Cumulative NRTI treatment time (years)*	6.44 (2.173 -- 11.667)	13.13 (5.73 -- 17.18)	0.008
Cumulative NNRTI treatment time (years)*	0 (0 - 1.35)	0 (0 - 2.42)	0.76
Cumulative PI treatment time (years)*	2.25 (0 - 5.822)	7.115 (3.91 - 10.06)	0.006
Cumulative ARV treatment time (years)*	11.71 (3.98 - 20.965)	21.305 (14.68 - 27.14)	0.003